<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02314897</url>
  </required_header>
  <id_info>
    <org_study_id>2014/00258</org_study_id>
    <nct_id>NCT02314897</nct_id>
  </id_info>
  <brief_title>Left Ventricular Pacing to Prevent Iatrogenic TR Pilot Study</brief_title>
  <official_title>Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Aims Pacemaker implantation for treating bradyarrhythmias typically involves
      placing a pacing lead through the tricuspid valve (TV) into the right ventricular (RV) apex.
      It is now known that tricuspid regurgitation (TR) frequently results from this and may lead
      to increased morbidity or mortality. Recently, left ventricular (LV) pacing through an
      epicardial vein via the coronary sinus has been widely practiced due to the advent of
      biventricular pacing. This lead does not cross the TV, potentially reducing the risk of TV
      dysfunction and may also reduce the risk of LV dysfunction. The investigators hypothesize
      that LV pacing will prevent the onset of new TR or worsening of pre-existing TR in patients
      undergoing pacemaker implantation.

      Methods Patients receiving a pacemaker for sick sinus syndrome (n=20) with an LV ejection
      fraction &lt;40% will be randomly allocated to receive either conventional RV pacing or LV
      pacing via the coronary sinus. Serial 2D and 3D transthoracic echocardiography will be
      performed before implantation, one day post implantation, then at 1 week, 1 month, 6 months
      and 1 year. The primary endpoints will be new onset TR and the diagnosis of at least moderate
      TR. Other endpoints include biventricular function, ventricular dyssynchrony, complications
      of device implantation, mortality and major cardiovascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that left ventricular pacing via a coronary sinus approach can reduce the
      incidence of significant tricuspid regurgitation after pacemaker implantation in patients
      with normal left ventricular function.

      The aim of this study is to compare the degree of tricuspid regurgitation caused by pacemaker
      implantation between the conventional techniques of implanting a ventricular lead implanted
      in the right ventricular apex versus implanting a ventricular lead in a left ventricular
      epicardial vein via a coronary sinus approach.

      The secondary objective of our study is to evaluate whether left ventricular pacing is also
      less likely to cause ventricular dyssynchrony and dysfunction than right ventricular apical
      pacing.

      This study is a single centre randomised clinical pilot study comparing 2 different lead
      implantation techniques to be assessed using both imaging techniques and follow up for
      clinical outcomes.

      (i) Proposed study interventions The procedures in both arms of the study will be identical
      except for where the ventricular lead is placed. All parts of these procedures, including all
      the implanting equipment and pacing leads are standard routine clinical practice. The left
      ventricular leads used in this study are routinely used for pacing the left ventricle in
      patients receiving biventricular pacemakers or defibrillators for heart failure.

      The implant site will be the left or right prepectoral region and venous access will be via
      either an axillary or subclavian vein approach. These choices will be left to the implanting
      physician's discretion. Once venous access has been established successfully the patient will
      then be randomly allocated to either of the study arms.

      Patients randomized to have an LV lead will have a long coronary sinus sheath inserted which
      will be used to perform an occlusive venogram of the coronary sinus to determine if there are
      veins suitable for left ventricular lead placement. Those in the left ventricular pacing arm
      will instead have a left ventricular epicardial pacing lead placed as apically as possible in
      a large calibre left ventricular branch of the coronary sinus.

      Patients in the right ventricular apical pacing arm will have an endocardial active fixation
      pacing leads placed in the right ventricular apex in the conventional manner.

      Patients in both arms will then go on to have a right atrial active fixation lead placed in
      the right atrial appendage.

      (ii) Methods for protecting against other sources of bias All patients referred to our
      Arrhythmia Service will be assessed for suitability to take part in this study. Once
      recruited, study subjects will be block randomised in a 1:1 fashion to either conventional
      right ventricular lead implantation or left ventricular coronary sinus lead implantation.
      They will be blinded to their allocation during the course of this study to remove any bias.

      Assessment of the echocardiograms will be performed by 2 investigators who are not blinded to
      the patient's treatment allocation. This is because the pacemaker lead is nearly always well
      visualised during echocardiographic studies making blinding impossible. However, the main
      outcomes of this study will be quantitative measures of TR and biventricular function derived
      from 3D echocardiography rather than qualitative measures used in previous studies and this
      will protect against bias that may be caused by the echocardiogram assessors knowing the
      allocation of the patients. The studies will also be assessed for interobserver and
      intraobserver variability to look for the likelihood of bias.

      (iii) Duration of follow up period Patients will be seen post discharge at 1 week for wound
      care and at 1 months, 6 months and 12 months for pacemaker checks in the pacemaker clinic.

      (iv) Frequency and duration of follow-up The scheduled follow up is as follows. Note that all
      transthoracic echocardiography studies will include both 2D and 3D echocardiography

        1. Pre implant: transthoracic echocardiography

        2. Pacemaker implantation: randomisation when venous access is achieved. Blood samples
           taken for biomarker assays.

        3. Post implant day 1: Pacemaker check, transthoracic echocardiography

        4. Post implant week 1: Wound check, pacemaker check, transthoracic echocardiography

        5. Post implant month 1: Wound check, pacemaker check, transthoracic echocardiography

        6. Post implant month 6: Pacemaker check, transthoracic echocardiography, blood samples
           taken for biomarker assays.

        7. Post implant month 12: Pacemaker check, transthoracic echocardiography
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of moderate or worse TR post implantation</measure>
    <time_frame>6 months</time_frame>
    <description>At least moderate of worsening of tricuspid regurgitation at 6 months post implantation on echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biventricular ventricular function and dyssynchrony</measure>
    <time_frame>6 months</time_frame>
    <description>Echocardiographically determined LV function, RV function, interventricular and intra ventricular dyssynchrony at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiovascular mortality, hospitalizations, heart failure, stroke, MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of heart failure</measure>
    <time_frame>6 months</time_frame>
    <description>Change in plasma concentrations over 6 months of NT-proBNP, hsTnT and GDF15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lead performance parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Change in lead parameters over 6 months, including sensed R wave amplitude, impedance, capture threshold.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural complications and device related complications</measure>
    <time_frame>6 months</time_frame>
    <description>Procedural complications and device related complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Sick Sinus Syndrome</condition>
  <arm_group>
    <arm_group_label>LV pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Left ventricular pacing lead implanted via coronary sinus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RV pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional right ventricular pacing lead.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LV pacing</intervention_name>
    <description>Left ventricular pacing lead implanted via the coronary sinus.</description>
    <arm_group_label>LV pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RV pacing</intervention_name>
    <description>Conventional right ventricular pacing.</description>
    <arm_group_label>RV pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing dual chamber permanent pacemaker implantation for sick sinus
             syndrome. This is defined as symptomatic sinus node dysfunction manifest as sinus
             pauses or excessive sinus bradycardia and is diagnosed on continuous ECG monitoring or
             ambulatory ECG recording (Holter study).

          2. Aged â‰¥21 years and able to give informed consent. The age limit is so that all
             patients are able to give informed consent personally.

        Exclusion Criteria:

        1. Left ventricular ejection fraction &lt;40%. 2. Mobitz Type 2 second degree atrioventricular
        block, 2:1 atrioventricular block, high degree atrioventricular block or complete heart
        block.

          1. Life expectancy less than 1 year due to medical co-morbidities.

          2. Previous mechanical prosthetic tricuspid valve replacement, precluding the
             implantation of a right ventricular apical lead.

          3. Tricuspid regurgitation that is at least moderate in severity.

          4. Complex congenital heart disease precluding the placement of either a right
             ventricular apical lead or left ventricular lead via the coronary sinus

          5. Vascular or coronary sinus anatomy unfavourable to either conventional RV lead or left
             ventricular lead implantation as confirmed on a coronary sinus venography at the time
             of implantation.

          6. Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toon Wei Lim, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Chia</last_name>
    <phone>65-6772 7563</phone>
    <email>medccpt@nus.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Office of Biomedical Research</last_name>
    <phone>65-6516 8425</phone>
    <email>obr@nuh.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toon Wei Lim, MBBS, PhD</last_name>
      <phone>65-67725286</phone>
      <email>toon_wei_lim@nuhs.edu.sg</email>
    </contact>
    <contact_backup>
      <last_name>Office of Biomedical Research</last_name>
      <phone>65-65168425</phone>
      <email>obr@nuh.com.sg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sick Sinus Syndrome</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

